| melanoma
Kimmtrak vs Braftovi
Side-by-side clinical, coverage, and cost comparison for melanoma.Deep comparison between: Kimmtrak vs Braftovi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsBraftovi has a higher rate of injection site reactions vs Kimmtrak based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Braftovi but not Kimmtrak, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Kimmtrak
Braftovi
At A Glance
IV infusion
Weekly
gp100/CD3 T cell engager
Oral
Once daily
BRAF inhibitor
Indications
- melanoma
- melanoma
- Colorectal Carcinoma
- Non-Small Cell Lung Carcinoma
Dosing
Melanoma 20 mcg IV on Day 1, 30 mcg IV on Day 8, 68 mcg IV on Day 15, then 68 mcg IV once weekly thereafter; administer by intravenous infusion over 15-20 minutes.
melanoma, Non-Small Cell Lung Carcinoma 450 mg (six 75 mg capsules) orally once daily in combination with binimetinib until disease progression or unacceptable toxicity.
Colorectal Carcinoma 300 mg (four 75 mg capsules) orally once daily until disease progression or unacceptable toxicity, in combination with biweekly cetuximab and mFOLFOX6 or FOLFIRI, or weekly cetuximab.
Contraindications
—
—
Adverse Reactions
Most common (>=30%) Cytokine release syndrome, rash, pyrexia, pruritus, fatigue, nausea, chills, abdominal pain, edema, hypotension, dry skin, headache, vomiting
Serious Cytokine release syndrome, skin reactions, elevated liver enzymes, rashes, pyrexia, hypotension
Most common (>=25%) Fatigue, nausea, vomiting, diarrhea, abdominal pain, arthralgia, peripheral neuropathy, decreased appetite, rash, constipation, musculoskeletal pain, hemorrhage, pyrexia.
Serious New primary malignancies, cardiomyopathy, hepatotoxicity, hemorrhage, uveitis, QT prolongation, embryo-fetal toxicity.
Pharmacology
Tebentafusp-tebn is a bispecific gp100 peptide-HLA-A*02:01 directed TCR CD3 T cell engager; it binds to gp100 peptide on HLA-A*02:01-positive uveal melanoma cells and activates polyclonal T cells to release inflammatory cytokines and cytolytic proteins, resulting in direct lysis of uveal melanoma tumor cells.
Encorafenib is a kinase inhibitor that targets BRAF V600E as well as wild-type BRAF and CRAF, blocking constitutively activated BRAF kinase signaling driven by BRAF V600 mutations that stimulates tumor cell growth; in combination with binimetinib, it targets two kinases in the RAS/RAF/MEK/ERK pathway for greater anti-tumor activity.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Kimmtrak
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Braftovi
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Kimmtrak
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Braftovi
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (0/8)
Humana
Kimmtrak
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Braftovi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Melanoma: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0/fillfill
Braftovi Co-Pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
KimmtrakView full Kimmtrak profile
BraftoviView full Braftovi profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.